Polynovo’s FY20 Product Sales Likely To At Least Double FY19, Record US sales in June

  • Jul 10, 2020 AEST
  • Team Kalkine

PolyNovo Limited (ASX:PNV) provided a trading update and stated that the Company witnessed record US sales in June 2020, and from July 2019 to 30 June 2020 there has been 67% rise in hospital account in the US.

The Company reiterates earlier guidance that product sales for FY20 are expected to at least double than FY19.

Moreover, PNV disclosed that sales for the June quarter were 33% higher than the March quarter but including a record US result for June.

PNV quoted at A$2.430 at AEST 12:06 PM.


The video has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above video is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. Kalkine does not in any way endorse or recommend individuals, products or services that may be discussed on this site.


There is no one left untouched by the charm of the multibillion-dollar global boom in cannabis. Its glorious journey from a criminalized drug to being used in over 20 countries for treating medical conditions.

No wonder the cannabis stocks are on the edge of a green rush. Don’t miss out on the happenings in the cannabis sector and take advantage of the growth phase of this sector by subscribing to our report on Marijuana stocks in Australia.

Find out the drivers for the rise in cannabis stock rates Even though the cannabis sector is in its growing phase, Australian cannabis stocks have already started to rise actively due to a hastily increasing patient base, and a legislative landscape that is gradually beginning to liberalise.

Outreach and future of cannabis stocks As countries liberalise regulation for medical and recreational use of cannabis, it is predicted that the industry would grow sharply in upcoming years The global cannabis market stands currently at around $8 billion and it is expected that the hemp derived CBD market to hit approximately $22 billion by 2022. 

Key Players in the sector Althea Group Holdings Limited (ASX: AGH) and Cann Group Limited (ASX: CAN) are amongst the top players. Other Australia cannabis market players are- MGC Pharmaceuticals Ltd (ASX: MXC), Elixinol Global Limited (ASX: EXL), THC Global Group Limited (ASX: THC), AusCann Group Holdings Limited (ASX: AC8)

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK